Bristol-Myers' growth portfolio eclipses legacy loss
The argument presented is that Bristol-Myers Squibb is reaching an operational turning point where revenue from its new growth portfolio is outpacing generic revenue erosion from patent cliffs.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.